Instructions Laferobion nasal spray 100,000 IU/ml bottle 5 ml
Composition
active ingredient: interferon alfa-2b;
1 ml of the drug contains 100,000 IU of recombinant human interferon alpha-2b;
Excipients: trometamol, trometamol hydrochloride, hypromellose, disodium edetate, lysine hydrochloride, potassium chloride, methyl parahydroxybenzoate (E 218), water for injections.
Dosage form
Nasal spray.
Main physicochemical properties: clear colorless liquid.
Pharmacotherapeutic group
Immunostimulants. Interferons. Interferon alpha-2b. ATX code L03A B05.
Pharmacological properties
Pharmacodynamics
LAFEROBION – antiviral, antimicrobial, anti-inflammatory, immunomodulatory, antiproliferative agent. The biological action of interferon is characterized by the following effects: antiviral – inhibits the replication of viruses (adenoviruses, influenza viruses, etc.) due to the inhibitory effect on the processes of transcription and translation; antiproliferative – inhibits cell reproduction (most DNA- and RNA-containing viruses); immunomodulation – increases the phagocytic activity of macrophages and specific cytotoxicity of lymphocytes against target cells. Interferon initiates the synthesis of a specific enzyme – protein kinase, which prevents translation due to the phosphorylation of one of the initiating factors of this process; activates a specific ribonuclease, which damages the viral matrix RNA. The effects of interferon also include: stimulation of the production of other cytokines, induction of specific enzymes.
Pharmacokinetics
Not studied.
Indication
Prevention and treatment of acute respiratory viral infections (ARVI):
in patients who frequently and for a long time suffer from upper respiratory tract diseases; in contact with patients with acute respiratory viral infections; in case of hypothermia; in case of seasonal increase in morbidity.
Contraindication
Hypersensitivity to interferon alfa-2b and other components of the drug, severe forms of allergic diseases in history; thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi's sarcoma; severe cardiovascular diseases; psoriasis; severe liver and/or kidney dysfunction; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); autoimmune hepatitis or other autoimmune diseases in history; suppression of myeloid hematopoiesis; pregnancy and breastfeeding.
Interaction with other medicinal products and other types of interactions
If you are taking any other medications, be sure to inform your doctor, and if you are self-medicating, consult your doctor about the possibility of using the drug.
Concomitant use of intranasal vasoconstrictor drugs is not recommended, as they contribute to dryness of the nasal mucosa.
Application features
The drug contains methyl parahydroxybenzoate, which may cause allergic reactions, including delayed ones, and in exceptional cases, bronchospasm.
The drug should not be used if the integrity and labeling of the package is broken, if the physical properties (color or transparency of the liquid) change, and after the expiration date.
To avoid the spread of infection, individual use of the vial is recommended.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Use during pregnancy or breastfeeding
Use is contraindicated.
Method of administration and doses
The drug is injected into each nasal passage.
1 spray dose = 1 short press on the dispenser.
Nasal spray application schedule:
Remove the protective cap from the bottle. Activate the micro-doser-sprayer by pressing (test spray). While in an upright position, place the tip of the nozzle into the nasal passage and press the pump-dispenser. Repeat the introduction into the second nasal passage. After use, close the bottle with the cap.
At the first signs of SARS (within 5 days)
Adults - 3 spray doses in each nasal passage 5–6 times a day (single dose - 30,000 IU, daily dose - 150,000 - 180,000 IU).
Children
Children aged 1 to 3 years - 2 spray doses in each nasal passage 3–4 times a day (single dose - 20,000 IU, daily dose - 60,000 - 80,000 IU).
Children aged 3 to 14 years - 2 spray doses in each nasal passage 4–5 times a day (single dose - 20,000 IU, daily dose - 80,000 - 100,000 IU).
Children aged 14 to 18 years - 3 spray doses in each nasal passage 5–6 times a day (single dose - 30,000 IU, daily dose - 150,000 - 180,000 IU).
For the prevention of respiratory viral infections in adults
During seasonal increases in incidence – once in the morning with an interval of 1–2 days.
Children
Use in children over 1 year of age at the first signs of SARS.
Overdose
There is no data on overdose of the drug.
Adverse reactions
General disorders: often - dose-dependent flu-like syndrome (chills, fever, headache and muscle pain, joint pain, fatigue, lethargy, sweating); rarely - nausea, vomiting, dizziness, hot flashes. Electrolyte imbalance. Hypersensitivity reactions to the drug, including anaphylactic shock, Quincke's edema, are possible.
Skin and subcutaneous tissue disorders: skin rash (in isolated cases), including herpetic, itching, hyperemia, skin edema, urticaria, dry skin, alopecia.
On the part of the endocrine system: thyroid dysfunction.
From the organs of vision: visual impairment, conjunctival hyperemia.
On the part of the digestive tract: loss of appetite, increased levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase.
Hepatobiliary system: liver dysfunction.
From the urinary system: renal dysfunction.
From the blood and lymphatic system: leukopenia, thrombocytopenia, anemia, nosebleeds.
From the cardiovascular system: arterial hypertension and hypotension, tachycardia.
From the nervous system: dizziness, sleep disturbances, ataxia, paresthesias, confusion, anxiety and depression, increased excitability, drowsiness.
Respiratory, thoracic and mediastinal disorders: cough, dyspnea.
If you experience any adverse reactions, you should consult a doctor.
Expiration date
2 years. Shelf life after opening the bottle, if stored at a temperature of 2 to 8 º C, is 10 days.
Storage conditions
Store in the original packaging to protect from light at a temperature of 2 to 8 ºС.
Keep out of reach of children.
Packaging
5 ml in a bottle sealed with a micro-dispenser; 1 bottle in a cardboard pack.
Vacation category
Without a prescription.
Producer
LLC "FZ "BIOPHARMA", Ukraine.
Location of the manufacturer and its business address
Ukraine, 09100, Kyiv region, Bila Tserkva, Kyivska st., 37.
